COVID-19：武田薬品､免疫グロブリンの治験開始：18カ国500人参加（動画）：
COVID-19: Takeda immunoglobulin trial started: 500 from 18 countries：
COVID-19：武田制药免疫球蛋白试验开始：来自18个国家的500名参与者
武田薬品：
ー国内外の製薬企業13社の連合組織ー
10月9日、「高度免疫グロブリン製剤」の治験を始めたと発表した。
「高度免疫グロブリン製剤」：
「新型コロナウイルス感染症にかかって回復した患者の抗体」を濃縮、精製してつくる。
日本を含む18カ国500人が治験に参加する。
治験では：
- 入院を必要とする患者をランダムに2グループに分け、
- 片方には、抗ウイルス薬レムデシビルに加えて製剤を1回点滴、
- もう片方のグループには、レムデシビルと、薬効のない偽薬を点滴。
重症化を防ぐ効果があるかなどを調べる。
朝日新聞デジタル
https://www.asahi.com/articles/ASNB95SF2NB9PLZU001.html
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine
is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
The CoVIg-19 Plasma Alliance
urges anyone who has recovered from COVID-19 to consider donating plasma.
The CoVIg-19 Plasma Alliance,
an unprecedented collaboration of leading plasma companies supported by global organizations outside the plasma industry,
today confirmed that patients are now being enrolled in the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Phase 3 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease.
If successful, the Alliance’s H-Ig may become one of the earliest treatment options for hospitalized COVID-19 patients.